ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up

Core Insights - Esperion Therapeutics (ESPR) has reached a settlement with Dr. Reddy's Laboratories (RDY) regarding patents for Nexletol and Nexlizet, preventing RDY from launching generic versions in the U.S. before April 19, 2040, under certain conditions [1][6] - Following the announcement, Esperion's shares increased by 13.8%, and the stock has risen 50% year-to-date, outperforming the industry growth of 14.1% [2] Patent and Litigation Summary - The settlement resolves patent litigation initiated by Esperion against RDY's abbreviated new drug application (ANDA) for generic versions of Nexletol and Nexlizet [2][5] - All disputes concerning the validity or infringement of U.S. Patent No. 7,335,799 have been resolved with this settlement [5][6] - Other patents involved in ongoing litigation are set to expire in March 2036 and June 2040 [7] Product Performance - Nexletol and Nexlizet are marketed as Nilemdo and Nustendi in international markets, with Esperion earning royalties from these sales [8] - In the first half of 2025, net product sales of Nexletol and Nexlizet in the U.S. grew by 42%, indicating strong prescription growth [9]